Affinity DataIC50: 0.550nMAssay Description:JAK2 enzyme activity assays utilize catalytic domain (JH1, amino acids 808-1132) of human JAK2 expressed as N-terminal His-tagged protein in a baculo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:JAK2 JH1 binding assay utilizes catalytic domain (JH1, amino acids 826-1132) of human JAK2 expressed as N-terminal FLAG-tagged, biotinylated protein ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:JAK2 enzyme activity assays utilize catalytic domain (JH1, amino acids 808-1132) of human JAK2 expressed as N-terminal His-tagged protein in a baculo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:JAK2 enzyme activity assays utilize catalytic domain (JH1, amino acids 808-1132) of human JAK2 expressed as N-terminal His-tagged protein in a baculo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:JAK2 enzyme activity assays utilize catalytic domain (JH1, amino acids 808-1132) of human JAK2 expressed as N-terminal His-tagged protein in a baculo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:JAK2 JH1 binding assay utilizes catalytic domain (JH1, amino acids 826-1132) of human JAK2 expressed as N-terminal FLAG-tagged, biotinylated protein ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:JAK2 JH1 binding assay utilizes catalytic domain (JH1, amino acids 826-1132) of human JAK2 expressed as N-terminal FLAG-tagged, biotinylated protein ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:JAK2 JH1 binding assay utilizes catalytic domain (JH1, amino acids 826-1132) of human JAK2 expressed as N-terminal FLAG-tagged, biotinylated protein ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK6/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <20nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair